Medison Pharma
Privately held: no public share price · Israel
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
fostamatinib(Tavalisse) | Approved | Spleen tyrosine kinase (Syk)Small molecule | Immune Thrombocytopenia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.